Home' Australian Pharmacist : Australian Pharmacist May 2015 Contents Australian Pharmacist May 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer.
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD credits.
PSA members can answer online at www.psa.org.au.
• Login to submit your answers online. If you
do not have member access details, you can
request them via a link from the login page.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers online before
1 July 2017 at www.psa.org.au and
receive automatic feedback.
1. Apixaban exerts it’s anticoagulant
a) Causing thrombin formation leading to
the development of thrombi.
b) Inhibiting Vitamin K epoxide reductase.
c) Directly inhibiting activated factor X in
the blood coagulation cascade.
d) Binding to and inhibiting the activity of
thrombin therefore prevent blood clot
e) Activating antithrombin III, which
inhibits thrombin and factor Xa.
2. Apixiban is indicated for the
a) Prevention of VTE in adult patients who
have undergone an elective total hip
b) Prevention of VTE in adult patients who
have undergone an elective total knee
c) Prevention of stroke and systemic
embolism in patients who have non-
valvular atrial fibrillation (NVAF) and at
least one additional risk factor for stroke.
e) All of the above.
3. What is the correct recommendation
regarding the use of apixaban
for prevention of VTE in an adult
patient, weighing 75 kg with a serum
creatinine of 100 micromol/L, who
has undergone an elective TKR?
a) Apixaban not recommended for use.
b) A dose of 2.5 mg twice daily for
c) A dose of 2.5 mg once daily for
d) A dose of 2.5 mg twice daily for
e) A dose of 2.5 mg once daily for
4. What is the correct recommendation
regarding the use of apixaban for
prevention of stroke in a 85-year-old
man with NVAF who weighs 54 kg
and has a serum creatinine of 160
a) A dose of 2.5 mg once daily.
b) A dose of 2.5 mg twice daily.
c) Apixaban not recommended for use.
d) A dose of 5mg twice daily.
5. Which of the following is true
regarding the use of apixaban in
combination with itraconazole and
a) Itraconazole will increase the
metabolism of apixaban.
b) Ritonavir will increase the excretion of
c) Ritonavir and itraconazole will decrease
the concentration of apixaban.
d) Itraconazole will decrease the
metabolism of apixaban.
1. National Health and Medical Research Council. Clinical
practice guideline for the prevention of venous
thromboembolism (deep vein thrombosis and pulmonary
embolism) in patients admitted to Australian hospitals.
Melbourne: National Health and Medical Research Council;
2009. At: www.nhmrc.gov.au/_files_nhmrc/publications/
2. Cardiovascular Expert Group. Therapeutic guidelines:
cardiovascular. Melbourne: Therapeutic Guidelines Limited;
3. Dickson B. Venous thrombosis: on the history of Virchow ’s
triad. Univ Toronto Med J. 2004;81(166).
4. Bagot CN, Arya R. Virchow and his triad: a question of
attribution. Br J Haematol 2008;143(2):180–90 .
5. National Institute for Health and Care Excellence. Apixaban
for the prevention of venous thromboembolism after total
hip or knee replacement in adults 2012. At: www.nice.org.
6. Hanna MS, Mohan P, Knabb R, et al. Development of
apixaban: a novel anticoagulant for prevention of stroke
in patients with atrial fibrillation. Ann N Y Acad Sci.
7. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2012.
8. Nieto JA, Espada NG, Merino RG, et al. Dabigatran,
rivaroxaban and apixaban versus enoxaparin for
thomboprophylaxis after total knee or hip arthroplasty:
pool-analysis of phase III randomized clinical trials. Thromb
9. Huisman MV, Quinlan DJ, Dahl OE, et al Enoxaparin versus
dabigatran or rivaroxaban for thromboprophylaxis after hip
or knee arthroplasty: Results of separate pooled analyses of
phase III multicenter randomized trials. Circ Cardiovasc Qual
10. Neumann I, Rada G, Claro JC, et al. Oral direct factor Xa
inhibitors versus low-molecular-weight heparin to prevent
venous thromboembolism in patients undergoing total
hip or knee replacement: a systematic review and meta-
analysis. Ann Intern Med. 2012;156(10):710–9 .
11. Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et
al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin
for thromboprophylaxis after total hip or knee replacement:
systematic review, meta-analysis, and indirect treatment
comparisons. BMJ 2012;344:e3675.
12. Loke YK, Kwok CS. Dabigatran and rivaroxaban for
prevention of venous thromboembolism--systematic
review and adjusted indirect comparison. J Clin Pharm Ther
13. Adam SS, McDuffie JR, Lachiewicz PF, et al. Comparative
effectiveness of new oral anticoagulants and standard
thromboprophylaxis in patients having total hip or
knee replacement: a systematic review. Ann Intern Med
14. Garcia D, Libby E, Crowther MA. The new oral
anticoagulants. Blood 2010;115(1):15–20.
15. Lassen MR, Davidson BL, Gallus A. The efficacy and
safety or apixaban, an oral, direct factor Xa inhibtor, as
thromboprophylaxis in patients following total knee
replacement. J Thromb Haemost 2007;5(12): 2368–75.
16. Lassen MR, Gallus A, Raskob GE. Apixaban versus
enoxaparin for thoromboprophylaxis after hip replacement.
N Engl J Med 2010;363: 2487–98 .
17. Eikelboom JW, O’Donnell M, Yusuf S, et al. Rationale and
design of AVERROES: apixaban versus acetylsalicylic acid to
prevent stroke in atrial fibrillation patients who have failed
or are unsuitable for vitamin K antagonist treatment. Am H
18. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for
reduction in stroke and other Thromboembolic events in
atrial fibrillation (ARISTOTLE) trial: design and rationale. Am
H J 2010;159(3):331–9.
Links Archive Australian Pharmacist April 2015 Australian Pharmacist June 2015 Navigation Previous Page Next Page